The role of glucagon-like peptide-1 receptor agonists in cardiometabolic health management

Glucagon-like peptide-1 receptor agonists (GLP-1) represent an innovative class of hypoglycemic drugs, the clinical effects of which have gone far beyond glycemic control. The wide prevalence of GLP-1 receptors in organs and tissues of the human body provides many clinically significant pleiotropic effects of GLP-1. The results of a series of large randomized clinical trials demonstrated the high efficacy, good tolerability and safety of GLP-1 agonists in the management of cardiometabolic health, which determined their preferential position in clinical guidelines. A special place in the line of drugs of the GLP-1 receptor agonist class is occupied by liraglutide and semaglutide, due to their special additional effects on weight loss and effect on major cardiovascular outcomes, which allowed to expand the indications for their use in the treatment of obesity and reduction of CVD and overall mortality. The article presents a literature review of current data on the mechanisms of action and metabolic effects of GLP-1 receptor agonists.

1. Ndumele CE, Rangaswami J, Chow SL et al.; American Heart Association. Cardiovascular-kidney-metabolic health: A Presidential Advisory from the American Heart Association. Circulation. 2023; 148(20): 1606–35. doi: 10.1161/CIR.0000000000001184.

2. Larque E, Labayen I, Flodmark CE et al. From conception to infancy: Early risk factors for childhood obesity. Nat Rev Endocrinol. 2019; 15(8): 456–78. doi: 10.1038/s41574-019-0219-1.

3. World Obesity Federation. World obesity atlas 2023.URL: https://data.worldobesity.org/publications/?cat=19 (date of access – 01.12.2024).

4. The GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar MH, Reitsma MB et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017; 377(1): 13–27. doi: 10.1056/NEJMoa1614362.

5. Jendle J, Birkenfeld AL, Polonsky WH et al. Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials. Diabetes Obes Metab. 2019; 21(10): 2315–26. doi: 10.1111/dom.13816.

6. Ishii H, Hansen BB, Langer J et al. Effect of orally administered semaglutide versus dulaglutide on diabetes-related quality of life in japanese patients with type 2 diabetes: The PIONEER 10 randomized, active-controlled trial. Diabetes Ther. 2021; 12(2): 613–23. doi: 10.1007/s13300-020-00985-w

7. Wilding JPH, Batterham RL, Calanna S et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021; 384(11): 989–1002. doi: 10.1056/NEJMOA2032183.

8. Irfan H. Obesity, cardiovascular disease, and the promising role of semaglutide: Insights from the SELECT trial. Curr Probl Cardiol. 2024; 49(1 Pt A): 102060. doi: 10.1016/j.cpcardiol.2023.102060.

9. Peng W, Zhou R, Sun ZF et al. Novel insights into the roles and mechanisms of GLP-1 receptor agonists against aging-related diseases. Aging Dis. 2022; 13(2): 468–90. doi: 10.14336/AD.2021.0928.

10. Wharton S, Batterham RL, Bhatta M et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring) 2023; 31(3): 703–15. doi: 10.1002/oby.23673.

11. Gabery S, Salinas CG, Paulsen SJ et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020; 5(6): e133429. doi: 10.1172/jci.insight.133429.

12. [Xi Y, Xinyao H, Xiangguo L. Systematic review of the effect of semaglutide on weight loss in non-diabetic overweight or obese adults. Guangxi Med 2022; 44: 2285–91 (In Chinese)].

13. Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S et al. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr. 2024; 11: 1398059. doi: 10.3389/fnut.2024.1398059.

14. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022; 57: 101351. doi: 10.1016/j.molmet.2021.101351.

15. Garvey WT, Batterham RL, Bhatta M et al.; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nat Med. 2022; 28(10): 2083–91. doi: 10.1038/s41591-022-02026-4.

16. Листок-вкладыш – информация для пациента. Семавик® Некст, 0,25 мг/доза, раствор для подкожного введения. Семавик® Некст, 0,5 мг/доза, раствор для подкожного введения. Семавик® Некст, 1 мг/доза, раствор для подкожного введения. Семавик® Некст, 1,7 мг/доза, раствор для подкожного введения. Семавик® Некст, 2,4 мг/доза, раствор для подкожного введения. Соответствует экспертному отчету от 01.10.2024, № 21153 (последовательность 0002).

17. Marso SP, Daniels GH, Brown-Frandsen K et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311–22. doi: 10.1056/NEJMoa1603827.

18. Marso SP, Bain SC, Consoli A et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834–44. doi: 10.1056/NEJMoa1607141.

19. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193): 121–30. doi: 10.1016/S0140-6736(19)31149-3.

20. Aldiss P, Davies G, Woods R et al. ‘Browning’ the cardiac and perivascular adipose tissues to modulate cardiovascular risk. Int J Cardiol. 2017; 228: 265–74. doi: 10.1016/j.ijcard.2016.11.074.

21. Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail. 2023; 11(8 Pt 1): 1000–10. doi: 10.1016/j.jchf.2023.05.010.

22. Kosiborod MN, Petrie MC, Borlaug BA et al.; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024; 390(15): 1394–407. doi: 10.1056/NEJMoa2313917.

23. Deanfield J, Verma S, Scirica BM et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial. Lancet 2024; 404(10454): 773–86. doi: 10.1016/S0140-6736(24)01498-3.